Here are the 424B prospectus supplements from ProQR Therapeutics N.V. (PRQR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PRQR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRQR filings page.
ProQR Therapeutics N.V. is registering the resale, from time to time, of up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company is not selling shares in this offering and will receive no proceeds from any resale.
The shares trade on Nasdaq under “PRQR”; the last reported price was $1.81 per share on July 2, 2026. Ordinary shares outstanding were 105,362,551 as of March 31, 2026 and are expected to be 141,121,476 after including June 2026 equity issuances; this is a baseline figure, not the amount being offered.
ProQR is a clinical-stage biotechnology company developing RNA editing therapies using its Axiomer platform, with lead liver and CNS programs such as AX-0810 for cholestatic diseases and additional collaborations with Lilly and Ginkgo Bioworks. As of March 31, 2026, cash and cash equivalents were €81,088 thousand against total debt of €15,733 thousand.
ProQR Therapeutics N.V. is offering 27,624,310 ordinary shares at a public offering price of $1.81 per share. Concurrently, ProQR has a separately negotiated private placement with Eli Lilly and Company for 5,100,780 ordinary shares at the same public offering price; that private placement is not registered as part of this offering but will close simultaneously, and the closing of the offering is not contingent on the private placement. The underwriters expect to deliver the shares on or about June 26, 2026. ProQR reports estimated net proceeds from the offering together with the concurrent private placement of approximately $55.8 million, and states it intends to use proceeds to fund research and clinical development, working capital, capital expenditures and other general corporate purposes. ProQR expects 141,119,032 ordinary shares to be outstanding immediately after this offering and the concurrent private placement.